Group 1: Market Overview - The market experienced a decline with the ChiNext index leading the drop, and the STAR 50 index falling over 6% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.54 trillion yuan, an increase of 180.2 billion yuan compared to the previous trading day [1] - Nearly 3,000 stocks in the market saw a decline, while sectors such as retail, food, paper, and photovoltaic performed well [1] Group 2: Company News - Heng Rui Medicine received approval for clinical trials of HRS-4729 injection, a self-developed peptide drug targeting multiple receptors, with no similar products approved in the market [2] - Ningbo Construction announced that its subsidiaries won construction projects with a total bid amount of 1.117 billion yuan [3] Group 3: External Market - The S&P 500 index reached a new closing high, with the Dow Jones up 0.77%, S&P 500 up 0.83%, and Nasdaq up 0.98% [4] - Chip stocks showed strong performance, with Western Digital rising over 5% and Micron Technology increasing over 4% [4] - Major tech stocks also performed well, with Amazon rising over 4%, marking the largest increase since May [4]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances metabolic regulation compared to dual-target therapies [1] - The drug promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat [1]